Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

Dyne Therapeutics (DYN) is stepping into a pivotal week, with investors laser focused on tomorrow’s topline readout from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for DYNE-251 ...

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target. 10 stocks we like better than Dyne Therapeutics › Dyne ...

The first officer or copilot is second in command to the captain and assists in flight preparations and the operation of the ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion ...

Erling Haaland’s 149th goal in a Manchester City shirt has seen him move ahead of Club legend Francis Lee. The unstoppable Norwegian got there with his second strike against West Ham on Saturday in ...

NASDAQ: ABVX: $68 million (14.9% of AUM) NASDAQ: AMLX: $62.6 million (13.7% of AUM) NASDAQ: JAZZ: $39.6 million (8.7% of AUM) NASDAQ: DYN: $33.8 million (7.4% of AUM) NASDAQ: COGT: $29.1 million (6.4% ...